Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy

Brenner, Barry M., Cooper, Mark E., de Zeeuw, Dick, Keane, William F., Mitch, William E., Parving, Hans-Henrik, Remuzzi, Giuseppe, Snapinn, Steven M. +2 more·2001·New England Journal of Medicine
DOI 10.1056/nejmoa011161

Cited by (7,499)

Items 501–600 of 7,499

  1. Glucose, Obesity, Metabolic Syndrome, and Diabetes
    Tamara B. Horwich, Gregg C. Fonarow · 2010 · Journal of the American College of Cardiology
  2. Doença renal crônica: importância do diagnóstico precoce, encaminhamento imediato e abordagem interdisciplinar estruturada para melhora do desfecho em pacientes ainda não submetidos à diálise
    Marcus Gomes Bastos, Gianna Mastroianni Kirsztajn · 2011 · Brazilian Journal of Nephrology
  3. Aliskiren: the first renin inhibitor for clinical treatment
    Chris Jensen, Peter Herold, Hans Rudolf Brunner · 2008 · Nature Reviews Drug Discovery
  4. A causal link between oxidative stress and inflammation in cardiovascular and renal complications of diabetes
    Jay C. Jha, Florence Ho, Christopher Dan, Karin Agnes Maria Jandeleit-Dahm · 2018 · Clinical Science
  5. Dual Blockade of the Renin-Angiotensin System in Diabetic Nephropathy
    Kasper Rossing, Per Knud Christensen, Berit Ruud Jensen, Hans‐Henrik Parving · 2002 · Diabetes Care
  6. Phase 1 Study of Anti-CTGF Monoclonal Antibody in Patients with Diabetes and Microalbuminuria
    Sharon G. Adler, Sherwyn Leon Schwartz, Mark E. Williams, Carlos Arauz-Pacheco, Warren Kline Bolton, Tyson T. Lee, Dongxia Li, Thomas B. Neff, Pedro R. Urquilla, Kathryn Lea Sewell · 2010 · Clinical Journal of the American Society of Nephrology
  7. Role of Remission Clinics in the Longitudinal Treatment of CKD
    Piero Luigi Ruggenenti, Elena Perticucci, Paolo Cravedi, Vincenzo Gambara, Marco Costantini, Sanjib Kumar Sharma, Annalisa Perna, Giuseppe Remuzzi · 2008 · Journal of the American Society of Nephrology
  8. T lymphocytes mediate hypertension and kidney damage in Dahl salt-sensitive rats
    Carmen De Miguel, Satarupa Das, Hayley Lund, David L. Mattson · 2010 · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology
  9. SGLT-2 inhibitors and GLP-1 receptor agonists for nephroprotection and cardioprotection in patients with diabetes mellitus and chronic kidney disease. A consensus statement by the EURECA-m and the DIABESITY working groups of the ERA-EDTA
    Pantelis A. Sarafidis, Charles Joseph Ferro, Enrique Morales, Alberto Ortíz, Jolanta Małyszko, Radovan Hojs, Khaled Khazim, Robert Ekart, José Manuel Valdivielso, Denis P. Fouque et al. · 2019 · Nephrology Dialysis Transplantation
  10. Kidney Function and Outcomes in Patients Hospitalized With Heart Failure
    Ravi B. Patel, Gregg C. Fonarow, Stephen John Greene, Shuaiqi Zhang, Brooke Alhanti, Adam D. DeVore, Javed Butler, Paul A. Heidenreich, Joanna Huang, Michelle Maya Kittleson et al. · 2021 · Journal of the American College of Cardiology
  11. Unraveling the racial disparities associated with kidney disease1
    Keith C. Norris, Lawrence Y C Agodoa · 2005 · Kidney International
  12. Risk Scores for Predicting Outcomes in Patients with Type 2 Diabetes and Nephropathy
    William F. Keane, Zhongxin Zhang, Paulette A. Lyle, Mark Emmanuel Cooper, Dick de Zeeuw, Jean‐Pierre Grünfeld, James Phillip Lash, Janet B. McGill, William E. Mitch, Giuseppe Remuzzi et al. · 2006 · Clinical Journal of the American Society of Nephrology
  13. The Relationship between Hyperinsulinemia, Hypertension and Progressive Renal Disease
    Fadi A El-Atat, Sameer N. Stas, Samy I. McFarlane, James R. Sowers · 2004 · Journal of the American Society of Nephrology
  14. Effects of dapagliflozin in stage 4 chronic kidney disease
    Chertow, Glenn M., Vart, Priya, Jongs, Niels, Toto, Robert D., Gorriz, Jose Luis, Hou, Fan Fan, McMurray, John J.V., Correa-Rotter, Ricardo, Rossing, Peter, Sjöström, C. David et al. · 2021 · Journal of the American Society of Nephrology
  15. Kidney-Heart Interactions
    Tomás Berl, William L. Henrich · 2005 · Clinical Journal of the American Society of Nephrology
  16. Identification and Referral of Patients With Progressive CKD: A National Study
    L. Ebony Boulware, Misty U. Troll, Bernard G. Jaar, Donna I. Myers, Neil R. Powe · 2006 · American Journal of Kidney Diseases
  17. A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of AST-120 (Kremezin) in Patients With Moderate to Severe CKD
    Gerald Schulman, Rajiv Agarwal, Muralidhar Acharya, Tomás Berl, Samuel S. Blumenthal, Nelson P. Kopyt · 2006 · American Journal of Kidney Diseases
  18. Mycophenolate mofetil alleviates persistent proteinuria in IgA nephropathy
    Sydney C.W. Tang, Joseph C.K. Leung, Loretta Y.Y. Chan · 2005 · Kidney International
  19. 2015 Guidelines of the Taiwan Society of Cardiology and the Taiwan Hypertension Society for the Management of Hypertension
    Chern‐En Chiang, Tzung‐Dau Wang, Kwo-Chang Ueng, Tsung‐Hsien Lin, Hung‐I Yeh, Chung-Yin Chen, Yih-Jer Wu, Wei‐Chuan Tsai, Ting‐Hsing Chao, Chen-Huan Chen et al. · 2014 · Journal of the Chinese Medical Association
  20. Combined Blockade of the Renin-Angiotensin System With Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Type 1 Receptor Antagonists
    Michel Azizi, Joël Ménard · 2004 · Circulation
  21. Contrast-induced nephropathy
    NazarM. A. Mohammed, Ahmed Mahfouz, Katafan Achkar, Ihsan M. Rafie, Rachel Hajar · 2013 · Heart Views
  22. Effect of Telmisartan on Renal Outcomes
    Johannes F.E. Mann, Roland E. Schmieder, Leanne Dyal, Matthew J. McQueen, Helmut Schumacher, Janice Pogue, Xingyu Wang, Jeffrey L. Probstfield, Álvaro Avezum, Ernesto Cardona-Munoz et al. · 2009 · Annals of Internal Medicine
  23. Mycophenolate mofetil prevents the development of glomerular injury in experimental diabetes
    Ricardo Utimura, Clarice Kazue Fujihara, Ana Lúcia Mattar, Denise Maria Avancini Costa Malheiros, Irene de Lourdes Noronha, Roberto Zatz · 2003 · Kidney International
  24. Endothelial dysfunction as a potential contributor in diabetic nephropathy
    Takahiko Nakagawa, Katsuyuki Tanabe, Byron P. Croker, Richard J. Johnson, Maria B. Grant, Tomoki Kosugi, Qiuhong Li · 2010 · Nature Reviews Nephrology
  25. Prevention and Treatment of Diabetic Renal Disease in Type 2 Diabetes
    Giuseppe Remuzzi, Manuel L. Macia, Piero Luigi Ruggenenti · 2006 · Journal of the American Society of Nephrology
  26. Primary Prevention of Cardiovascular Disease and Type 2 Diabetes in Patients at Metabolic Risk: An Endocrine Society Clinical Practice Guideline
    James L. Rosenzweig, Ele Ferrannini, Scott M. Grundy, Steven M. Haffner, Robert J. Heine, Edward S. Horton, Ryuzo Kawamori · 2008 · The Journal of Clinical Endocrinology & Metabolism
  27. A Meta-Analysis Reporting Effects of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in Patients Without Heart Failure
    Gianluigi Savarese, Pierluigi Costanzo, John G.F. Cleland, Enrico Vassallo, Donatella Ruggiero, Giuseppe M.C. Rosano, Pasquale Perrone Filardi · 2012 · Journal of the American College of Cardiology
  28. Diabetic Kidney Disease: Pathophysiology and Therapeutic Targets
    Stephanie M. Toth‐Manikowski, Mohamed G. Atta · 2015 · Journal of Diabetes Research
  29. The renin-angiotensin system and diabetes: an update.
    Antônio Ribeiro‐Oliveira, Anelise Impelizieri Nogueira, Regina Maria Pereira, Walkíria Wingester Vilas Boas, Robson A.S. Santos, Ana Cristina Simões e Silva · 2008 · PubMed Central
  30. Comparison of different measures of urinary protein excretion for prediction of renal events
    Lambers Heerspink, Hiddo J., Gansevoort, Ron T., Brenner, Barry M., Cooper, Mark E., Parving, Hans Henrik, Shahinfar, Shahnaz, de Zeeuw, Dick · 2010 · Journal of the American Society of Nephrology
  31. Diabetes and end-stage renal disease; a review article on new concepts.
    Seyed Bahman Ghaderian, Fatemeh Hayati, Shokouh Shayanpour, Seyed Seifollah Beladi Mousavi · 2015 · PubMed Central
  32. Stopping Renin-Angiotensin System Inhibitors in Patients with Advanced CKD and Risk of Adverse Outcomes: A Nationwide Study
    Edouard L. Fu, Marie Evans, Catherine M. Clase, Laurie A. Tomlinson, Merel van Diepen, Friedo Wilhelm Dekker, Juan Jesús Carrero · 2020 · Journal of the American Society of Nephrology
  33. The Early Natural History of Nephropathy in Type 1 Diabetes
    Steinke, Julia M., Sinaiko, Alan R., Kramer, Michael S., Suissa, Samy, Chavers, Blanche M., Mauer, Michael, for the International Diabetic Nephropathy Study Group · 2005 · Diabetes
  34. Contrast-Induced Nephropathy
    Peter Andrew McCullough, Sandeep S. Soman · 2005 · Critical Care Clinics
  35. Kidney disease in diabetes: From mechanisms to clinical presentation and treatment strategies
    Carlo Alberto Ricciardi, Luigi Gnudi · 2021 · Metabolism
  36. Oral Paricalcitol in the Treatment of Patients With CKD and Proteinuria: A Randomized Trial
    Steven N. Fishbane, Harini Chittineni, Michal Packman, Paula Dutka, Nicole M Ali, Nicole M. Durie · 2009 · American Journal of Kidney Diseases
  37. Assessment and Management of Hypertension in Transplant Patients
    Matthew R. Weir, Ellen D. Burgess, James E. Cooper, Andrew Zoltan Fenves, David J.A. Goldsmith, Dianne B. McKay, Anita Mehrotra, Mark M. Mitsnefes, Domenic A. Sica, Sandra J. Taler · 2015 · Journal of the American Society of Nephrology
  38. The Role of the Renin-Angiotensin-Aldosterone System in Obesity-Related Renal Diseases
    Christiane Rüster, Günter Wolf · 2013 · Seminars in Nephrology
  39. Immunosenescence and Immunogenetics of Human Longevity
    Rita Ostan, L. Bucci, Miriam Capri, Stefano Salvioli, Maria Scurti, E. Pini, Daniela Monti, Claudio Franceschi · 2008 · NeuroImmunoModulation
  40. Renin-angiotensin system activation and interstitial inflammation in human diabetic nephropathy.
    S. Mezzano, A. Droguett, M. E. Burgos, L. Ardiles, C. Flores, C. Aros, I. Caorsi, Carlos P. Vío, M. Ruíz-Ortega, J. Egido · 2003 · Kidney international. Supplement
  41. Diabetic nephropathy: An update on pathogenesis and drug development
    Vikram Rao, Sean Hong Tan, Mayuren Candasamy, Subrat Kumar Bhattamisra · 2018 · Diabetes & Metabolic Syndrome Clinical Research & Reviews
  42. Mechanisms of Metabolic Acidosis–Induced Kidney Injury in Chronic Kidney Disease
    Donald E. Wesson, Jerry Buysse, David A. Bushinsky · 2020 · Journal of the American Society of Nephrology
  43. Hyperkalemia Associated with Use of Angiotensin‐Converting Enzyme Inhibitors and Angiotensin Receptor Blockers
    Marsha A. Raebel · 2011 · Cardiovascular Therapeutics
  44. Reduction of Diabetes-Induced Oxidative Stress, Fibrotic Cytokine Expression, and Renal Dysfunction in Protein Kinase Cβ–Null Mice
    Yuzuru Ohshiro, Ronald C.W., Yutaka Yasuda, Junko Hiraoka‐Yamamoto, Allen C. Clermont, Keiji Isshiki, Kunimasa Yagi, Emi Arikawa, Timothy S. Kern, George Liang King · 2006 · Diabetes
  45. Renoprotective Properties of Angiotensin Receptor Blockers beyond Blood Pressure Lowering
    Yuko Izuhara, Masaomi Nangaku, Reiko Inagi, Naoto Tominaga, Toru Aizawa, Kiyoshi Kurokawa, Charles van Ypersele de Strihou, Toshio Miyata · 2005 · Journal of the American Society of Nephrology
  46. Spironolactone in type 2 diabetic nephropathy: effects on proteinuria, blood pressure and renal function
    Anton H. van den Meiracker, Rini G. A. Baggen, Sacha Pauli, Anouk D. Lindemans, Arnold G. Vulto, Don Poldermans, Frans Boomsma · 2006 · Journal of Hypertension
  47. ACE Inhibitor Benefit to Kidney and Cardiovascular Outcomes for Patients with Non-Dialysis Chronic Kidney Disease Stages 3–5: A Network Meta-Analysis of Randomised Clinical Trials
    Yaru Zhang, Dandan He, Wei Zhang, Yue Xing, Yipeng Guo, Fuzhen Wang, Junya Jia, Tiekun Yan, Youxia Liu, Shan Lin · 2020 · Drugs
  48. Clinical Management of Hyperkalemia
    Biff F. Palmer, Juan Jesús Carrero, Deborah J. Clegg, Gates B. Colbert, Michael Emmett, Steven N. Fishbane, Debra J. Hain, Edgar V. Lerma, Macaulay A C Onuigbo, Anjay Rastogi et al. · 2020 · Mayo Clinic Proceedings
  49. Chronic kidney disease
    Paola Romagnani, Rajiv Agarwal, Juliana C.N. Chan, Adeera Levin, Robert Kalyesubula, Sabine Karam, Masaomi Nangaku, Bernardo Rodríguez‐Iturbe, Hans‐Joachim Anders · 2025 · Nature Reviews Disease Primers
  50. The renin–angiotensin–aldosterone system and glucose homeostasis
    Luther, James Matthew, Brown, Nancy J. · 2011 · Trends in Pharmacological Sciences
  51. Effect of patients’ risks and preferences on health gains with plasma glucose level lowering in type 2 diabetes mellitus
    Vijan, Sandeep, Sussman, Jeremy B., Yudkin, John S., Hayward, Rodney A. · 2014 · JAMA Internal Medicine
  52. Antihypertensive Treatment and Development of Heart Failure in Hypertension
    Sebastiano Sciarretta, Francesca Palano, Giuliano Tocci, Rossella Baldini, Massimo Volpe · 2010 · Archives of Internal Medicine
  53. Diabetes mellitus as a compelling indication for use of renin angiotensin system blockers: systematic review and meta-analysis of randomized trials
    Bangalore, Sripal, Fakheri, Robert, Toklu, Bora, Messerli, Franz H · 2016 · BMJ
  54. Interferon-γ Signaling Inhibition Ameliorates Angiotensin II–Induced Cardiac Damage
    Lajos Markó, Heda Kvakan, Joon-Keun Park, Fatimunnisa Qadri, Bastian Spallek, Katrina J. Binger, Edward P. Bowman, Markus Kleinewietfeld, Verena Fokuhl, Ralf Dechend et al. · 2012 · Hypertension
  55. Design and Baseline Characteristics of the Finerenone in Reducing Kidney Failure and Disease Progression in Diabetic Kidney Disease Trial
    Bakris, George L., Agarwal, Rajiv, Anker, Stefan D., Pitt, Bertram, Ruilope, Luis M., Nowack, Christina, Kolkhof, Peter, Ferreira, Anna C., Schloemer, Patrick, Filippatos, Gerasimos et al. · 2019 · American Journal of Nephrology
  56. Hyperkalemia after initiating renin-angiotensin system blockade: the Stockholm Creatinine Measurements (SCREAM) project
    Bandak, Ghassan, Sang, Yingying, Gasparini, Alessandro, Chang, Alex R., Ballew, Shoshana H., Evans, Marie, Arnlov, Johan, Lund, Lars H., Inker, Lesley A., Coresh, Josef et al. · 2017 · Journal of the American Heart Association
  57. Economic Implications of Evidence-Based Prescribing for Hypertension
    Michael A. Fischer, Jerry Avorn · 2004 · JAMA
  58. Diabetic Nephropathy: Where Hemodynamics Meets Metabolism
    Josephine Maree Forbes, Kei Fukami, Mark Emmanuel Cooper · 2007 · Experimental and Clinical Endocrinology & Diabetes
  59. Chronic Kidney Disease after Nonrenal Solid-Organ Transplantation
    Roy D. Bloom, Peter Philip Reese · 2007 · Journal of the American Society of Nephrology
  60. Supramaximal Dose of Candesartan in Proteinuric Renal Disease
    Ellen D. Burgess, Norman Muirhead, Paul René de Cotret, Anthony Chiu, Vincent Pichette, Sheldon W. Tobe · 2009 · Journal of the American Society of Nephrology
  61. ACE2 Deficiency Modifies Renoprotection Afforded by ACE Inhibition in Experimental Diabetes
    Chris Tikellis, Katarzyna Bialkowski, Josepha Pete, Karen Sheehy, Su Qui, Colin I. Johnston, Mark Emmanuel Cooper, Merlin C. Thomas · 2008 · Diabetes
  62. 25-Hydroxyvitamin D Levels, Race, and the Progression of Kidney Disease
    Michal L. Melamed, Brad C. Astor, Erin D. Michos, Thomas H. Hostetter, Neil R. Powe, Paul Muntner · 2009 · Journal of the American Society of Nephrology
  63. The gut–renal axis: do incretin-based agents confer renoprotection in diabetes?
    Marcel H.A. Muskiet, Mark M. Smits, Linde M. Morsink, Michaëla Diamant · 2013 · Nature Reviews Nephrology
  64. 10. Microvascular Complications and Foot Care
    American Diabetes Association · 2016 · Diabetes Care
  65. Progression of diabetic nephropathy
    Ryuichi Kikkawa, Daisuke Koya, Masakazu Haneda · 2003 · American Journal of Kidney Diseases
  66. Diabetic Kidney Disease
    Ryan Bonner, Oltjon Albajrami, James C. Hudspeth, Ashish Upadhyay · 2020 · Primary Care Clinics in Office Practice
  67. Angiotensin-Neprilysin Inhibition and Renal Outcomes in Heart Failure With Preserved Ejection Fraction
    Finnian R. Mc Causland, Martin P. Lefkowitz, Brian Lee Claggett, Nagesh S. Anavekar, Michele Senni, Mauro Gori, Pardeep S. Jhund, Martina M. McGrath, Milton Packer, Victor Chengwei Shi et al. · 2020 · Circulation
  68. Screening, Monitoring, and Treatment of Stage 1 to 3 Chronic Kidney Disease: A Clinical Practice Guideline From the American College of Physicians
    Amir Qaseem, ROBERT H. HOPKINS, Donna E. Sweet, Melissa Starkey, Paul Shekelle · 2013 · Annals of Internal Medicine
  69. Functional Interplay Between Angiotensin II and Nitric Oxide
    Yan Chen, Dong Soo Kim, Toru Aizawa, Bradford C. Berk · 2003 · Arteriosclerosis Thrombosis and Vascular Biology
  70. Renin-Angiotensin System and Angiotensin Receptor Blockers in the Metabolic Syndrome
    Abhiram Prasad, Arshed Ali Quyyumi · 2004 · Circulation
  71. Diabetic Nephropathy
    Lionel Henry Opie, Hans‐Henrik Parving · 2002 · Circulation
  72. Metabolic syndrome: a sympathetic disease?
    Schlaich, Markus, Straznicky, Nora, Lambert, Elisabeth, Lambert, Gavin · 2015 · The Lancet Diabetes & Endocrinology
  73. The association between congestive heart failure and chronic renal disease
    Donald S. Silverberg, Dov Wexler, Miriam Blum, Doron Schwartz, Adrian Iaina · 2004 · Current Opinion in Nephrology & Hypertension
  74. No Improvement of Patient or Graft Survival in Transplant Recipients Treated with Angiotensin-Converting Enzyme Inhibitors or Angiotensin II Type 1 Receptor Blockers
    Gerhard Opelz, Martin G. Zeier, Gunter Laux, Christian P. Morath, Bernd Döhler · 2006 · Journal of the American Society of Nephrology
  75. Post–Acute Kidney Injury Proteinuria and Subsequent Kidney Disease Progression
    Chi‐yuan Hsu, Vernon M. Chinchilli, Steven G. Coca, Prasad Devarajan, Nasrollah Ghahramani, Alan S. Go, Raymond K. Hsu, Talat Alp Ikizler, James S. Kaufman, Kathleen D. Liu et al. · 2020 · JAMA Internal Medicine
  76. Diabetic microvascular complications: can patients at risk be identified? A review
    Aniz Girach, David H. Manner, Massimo Porta · 2006 · International Journal of Clinical Practice
  77. Low-protein diet for diabetic nephropathy: a meta-analysis of randomized controlled trials
    Pan, Yu, Guo, Li Li, Jin, Hui Min · 2008 · The American Journal of Clinical Nutrition
  78. Therapeutic targets for treating fibrotic kidney diseases
    So-Young Lee, Sung-Il Kim, Mary E. Choi · 2014 · Translational research
  79. Treatment of Hypertension in Patients With Coronary Artery Disease
    Clive Rosendorff, Daniel T. Lackland, Matthew Allison, Wilbert S. Aronow, Henry R. Black, Roger Scott Blumenthal, Christopher Paul Cannon, James A. de Lemos, W.J. Elliott, Laura Findeiss et al. · 2015 · Hypertension
  80. Add-On Anti–TGF-β Antibody to ACE Inhibitor Arrests Progressive Diabetic Nephropathy in the Rat
    Ariela Benigni, Carla Zoja, Daniela Corna, Cristina Zatelli, Sara Conti, Marco Campana, Elena Gagliardini, Daniela Rottoli, Cristina Zanchi, Mauro Abbate et al. · 2003 · Journal of the American Society of Nephrology
  81. Diabetic Nephropathy
    American Diabetes Association · 2003 · Diabetes Care
  82. Proteomic analysis for the assessment of diabetic renal damage in humans
    Harald Mischak, Thorsten Kaiser, Michael Walden, Meike Hillmann, Stefan Wittke, A. Herrmann, Stefan Knueppel, Hermann G. Haller, Danilo Fliser · 2004 · Clinical Science
  83. Rationale, design and baseline characteristics of the CANagliflozin cardioVascular Assessment Study–Renal ( <scp>CANVAS‐R</scp> ): A randomized, placebo‐controlled trial
    Neal, Bruce, Perkovic, Vlado, Matthews, David R., Mahaffey, Kenneth W., Fulcher, Greg, Meininger, Gary, Erondu, Ngozi, Desai, Mehul, Shaw, Wayne, Vercruysse, Frank et al. · 2017 · Diabetes, Obesity and Metabolism
  84. The Comparative Efficacy and Safety of the Angiotensin Receptor Blockers in the Management of Hypertension and Other Cardiovascular Diseases
    Hazel Mae A. Abraham, Charles Michael White, William B. White · 2014 · Drug Safety
  85. Acute Kidney Injury and Progression of Diabetic Kidney Disease
    Samuel Mon-Wei Yu, Joseph Vincent Bonventre · 2018 · Advances in Chronic Kidney Disease
  86. Treatment of chronic kidney disease
    Jeffrey M. Turner, Carolyn A. Bauer, Matthew K. Abramowitz, Michal L. Melamed, Thomas H. Hostetter · 2011 · Kidney International
  87. Diabetic nephropathy--a review of the natural history, burden, risk factors and treatment.
    Olugbenga Edward Ayodele, Christopher Olutayo Alebiosu, Babatunde Lawal Salako · 2004 · PubMed Central
  88. A genome scan for diabetic nephropathy in African Americans
    Donald W. Bowden, Carla J. Colicigno, Carl D. Langefeld, Michèle M. Sale, Adrienne H. Williams, Pamela J. Anderson, Stephen S. Rich, Barry I. Freedman · 2004 · Kidney International
  89. III Diretriz Brasileira de Insuficiência Cardíaca Crônica
    Edimar Alcides Bocchi, Fabiana G. Marcondes‐Braga, Silvia Moreira Ayub‐Ferreira, Luís Eduardo Paim Rohde, Wilson Alves de Oliveira Junior, Dirceu Rodrigues Almeida, Maria da Consolação Vieira Moreira, Reinaldo B. Bestetti, Solange Bordignon, Azevedo,Clério et al. · 2009 · Americanae (AECID Library)
  90. Mineralocorticoid Receptor Antagonist Reduces Renal Injury in Rodent Models of Types 1 and 2 Diabetes Mellitus
    Christine Guo, Diego Martinez-Vasquez, Gonzalo P. Méndez, María Fernanda Toniolo, Tham M. Yao, Eveline M. Oestreicher, Taisuke Kikuchi, Nathalie Lapointe, Luminita H. Pojoga, Gordon H. Williams et al. · 2006 · Endocrinology
  91. Anti-Hypertensive Agents Inhibit In Vivo the Formation of Advanced Glycation End Products and Improve Renal Damage in a Type 2 Diabetic Nephropathy Rat Model
    Masaomi Nangaku, Toshio Miyata, Toshio Sada et al. · 2003 · Journal of the American Society of Nephrology
  92. Coronary Heart Disease in Patients With Diabetes
    Colin Berry, Jean‐Claude Tardif, Martial G. Bourassa · 2007 · Journal of the American College of Cardiology
  93. Predictors of heart failure among women with coronary disease
    Bibbins-Domingo, Kirsten, Lin, Feng, Vittinghoff, Eric, Barrett-Connor, Elizabeth, Hulley, Stephen B., Grady, Deborah, Shlipak, Michael G. · 2004 · Circulation
  94. Sulodexide Fails to Demonstrate Renoprotection in Overt Type 2 Diabetic Nephropathy
    David Packham, Rory S Wolfe, Anne T. Reutens, Tomás Berl, Hiddo J.L. Heerspink, Richard Rohde, Sara E. Ivory, Julia Lewis, Itamar Raz, Thomas B. Wiegmann et al. · 2011 · Journal of the American Society of Nephrology
  95. Diabetic Nephropathy: Worldwide epidemic and effects of current treatment on natural history
    Peter R Rossing · 2006 · Current Diabetes Reports
  96. Update on diagnosis, pathophysiology, and management of diabetic kidney disease
    Mai Sugahara, Wai Lun Will Pak, Tetsuhiro Tanaka, Sydney C.W. Tang, Masaomi Nangaku · 2021 · Nephrology
  97. Regression of Existing Glomerulosclerosis by Inhibition of Aldosterone
    Jean‐Claude Aldigier, Talerngsak Kanjanabuch, Lijun Ma, Nancy Jeanne Brown, Agnes B. Fogo · 2005 · Journal of the American Society of Nephrology
  98. Mapping time-course mitochondrial adaptations in the kidney in experimental diabetes
    Melinda T. Coughlan, Tuong-Vi Nguyen, Sally A. Penfold, Gavin C. Higgins, Vicki Thallas‐Bonke, Sih Min Tan, Nicole J. Van Bergen, Karly C. Sourris, Brooke E. Harcourt, David Ross Thorburn et al. · 2016 · Clinical Science
  99. Dual renin-angiotensin system blockade at optimal doses for proteinuria
    Gozewijn Dirk Laverman, Gerjan J Navis, Robert H. Henning, Paul E. de Jong, Dick de Zeeuw · 2002 · Kidney International
  100. Epidemiology of hypertensive kidney disease
    Udani, Suneel, Lazich, Ivana, Bakris, George L. · 2011 · Nature Reviews Nephrology